Human Immune Responses to Yellow Fever Vaccination
NCT00694655
Recruiting
The goal of this study is to use the live attenuated Yellow Fever Vaccine as a safe and effective model for viral infection to understand human immune response to viral antigens. Study participants will receive the yellow fever vaccine and participation in the study may be as short as one month or as long as one year, depending on immune responses.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
04/17/2024
Locations: The Hope Clinic of the Emory Vaccine Center, Decatur, Georgia
Conditions: Yellow Fever
Register for Updates
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
NCT05000216
Completed
This is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different additional doses of COVID-19 vaccine in participants with autoimmune disease requiring IS medications. All study participants will have negative serologic or suboptimal responses (defined as a Roche Elecsys® Anti-SARS-CoV-2 S result ≤200 U/mL) or a low immune response (defined as a Roche Elecsys® Anti-SARS-CoV-2 S result \>200 U/ml and ≤2500 U/mL) to their previous doses of COVID-19 v... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
04/08/2024
Locations: UCLA Medical Center: Division of Rheumatology, Los Angeles, California +28 locations
Conditions: Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Systemic Sclerosis (SSc), Pediatric SLE, Pediatric-Onset Multiple Sclerosis (POMS), Rheumatoid Arthritis (RA), Multiple Sclerosis (MS), Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM)
Register for Updates
Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults
NCT04927585
Completed
The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of polyvalent env (A,B,C,A/E)/gag (C) DNA and gp120 (A,B,C,A/E) protein vaccines (PDPHV201401) co-administered together with or without adjuvant in repeated doses in healthy, HIV-uninfected adults
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
04/07/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: HIV Infections
Register for Updates
A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older
NCT05540522
Completed
This is a Phase 3, randomized, observer-blinded study to evaluate the efficacy, safety, tolerability, and immunogenicity of a single dose of a quadrivalent influenza modRNA vaccine compared to licensed inactivated influenza vaccine in healthy adults 18 years of age and older.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2024
Locations: North Alabama Research Center, Athens, Alabama +373 locations
Conditions: Influenza, Human
Register for Updates
Flublok or Fluzone With Advax-CpG55.2 or AF03
NCT03945825
Completed
This is a Phase I, randomized, double blinded, clinical trial in up to 240 males and non-pregnant females, 18-45 years of age, inclusive, who are in good health and meet all eligibility criteria. This clinical trial is designed to assess the safety, reactogenicity and immunogenicity of either the 2018/2019 seasonal Fluzone or Flublok Quadrivalent Influenza Vaccine (QIV) manufactured by Sanofi Pasteur (SP) given without adjuvant or with one of two adjuvant formulations, AF03 or Advax-CpG55.2. Eig... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
03/28/2024
Locations: Emory University School of Medicine, Atlanta, Georgia +7 locations
Conditions: Influenza, Influenza Immunisation
Register for Updates
A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults
NCT05972993
Active Not Recruiting
The purpose of this study is to evaluate the safety, reactogenicity and immune responses of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA-CR-04 vaccine construct when administered in healthy adults previously vaccinated with SARS-CoV-2 mRNA vaccines.
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
03/27/2024
Locations: GSK Investigational Site, San Diego, California +3 locations
Conditions: COVID-19
Register for Updates
Vaccination for Recovered Inpatients With COVID-19 (VATICO)
NCT04969250
Completed
In this Phase 4, open-label trial, participants of the ACTIV-3/TICO clinical trial at selected sites who received certain pre-specified blinded investigational agents or placebo as part of that trial, and who have since achieved sustained recovery, and who are still \[TICO assignment\] blinded and who are still within 28 to 90 days after initial TICO randomization, will be randomized in this 2x2 factorial design to one of four groups: (i) immediate versus 12 week deferral of first dose administr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Cedars-Sinai Medical Center (Site 208-002), 8700 Beverly Blvd, Los Angeles, California +29 locations
Conditions: Covid19
Register for Updates
Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults
NCT05266456
Completed
The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 18 to 49 years of age in Phase 1. The Phase 2 will evaluate the safety, tolerability, and immunogenicity of a single injection of VAX-24 at 3 dose levels compared to PCV20 in adults aged 50 to 64 years of age in Phase 2.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
03/25/2024
Locations: CenExel RCA, Hollywood, Florida +12 locations
Conditions: Pneumococcal Vaccines
Register for Updates
Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer
NCT03848182
Terminated
The investigator is developing an immune therapy against pancreatic cancer. Immune cells, known as "T cells with tumor killing capacity", are involved in this immune therapy. In mice with pancreatic cance there is evidence that one tetanus toxoid (TT) vaccination (that patients receive from childhood) combined with Gemcitabine activates these killer T cells. (Gemcitabine improves T cell responses) These killer T cells are able to destroy tumor cells uploaded with TT protein (such studies are pla... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
03/25/2024
Locations: Albert Einstein College of Medicine, Bronx, New York
Conditions: Pancreatic Cancer
Register for Updates
A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines
NCT01979406
Completed
The purpose of this study is to evaluate 2 vaccine candidates against anthrax compared to the positive (vaccine) control as studied in normal healthy volunteers.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
03/15/2024
Locations: The Center for Pharmaceutical Research, Kansas City, Kansas +3 locations
Conditions: Anthrax Infection
Register for Updates
Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1
NCT01006798
Completed
The purpose of this study is to compare the safety and immunogenicity over a 9-month period of five different dosages of Ad4-H5-Vtn in volunteers (Vaccinees) who receive three doses of the study vaccine or placebo. In addition, transmission of Ad4-H5-Vtn will be evaluated in all Household Contacts residing with the vaccinated volunteers. Vaccinees also may participate in a substudy in which they receive a booster vaccination with the licensed Influenza Virus Vaccine, H5N1 (Sanofi Pasteur).
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
03/15/2024
Locations: University of Kentucky, Lexington, Kentucky +3 locations
Conditions: Bird Flu, Influenza
Register for Updates
Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults
NCT00053482
Completed
The objective of this study is to determine the minimum dose of ACAM2000 needed to produce a cutaneous reaction in at least 90% of a population of healthy adults at least 28 years of age and previously vaccinated against smallpox.
Gender:
ALL
Ages:
28 years and above
Trial Updated:
03/14/2024
Locations: PRA International, Lenexa, Kansas +2 locations
Conditions: Smallpox
Register for Updates